pBabe puro HA PIK3CA Citations (19)
Originally described in: The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM Proc Natl Acad Sci U S A. 2005 Dec 20. 102(51):18443-8. PubMed Journal
Articles Citing pBabe puro HA PIK3CA
| Articles |
|---|
| Lapatinib induces p27(Kip1)-dependent G(1) arrest through both transcriptional and post-translational mechanisms. Tang L, Wang Y, Strom A, Gustafsson JA, Guan X. Cell Cycle. 2013 Aug 15;12(16):2665-74. doi: 10.4161/cc.25728. Epub 2013 Jul 29. PubMed |
| Enhanced PI3K p110alpha signaling confers acquired lapatinib resistance that can be effectively reversed by a p110alpha-selective PI3K inhibitor. Brady SW, Zhang J, Seok D, Wang H, Yu D. Mol Cancer Ther. 2014 Jan;13(1):60-70. doi: 10.1158/1535-7163.MCT-13-0518. Epub 2013 Nov 18. PubMed |
| A p85alpha-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cells. Leavenworth JW, Verbinnen B, Yin J, Huang H, Cantor H. Nat Immunol. 2015 Jan;16(1):96-106. doi: 10.1038/ni.3050. Epub 2014 Dec 1. PubMed |
| Attenuation of the phosphatidylinositol 3-kinase/Akt signaling pathway by Porphyromonas gingivalis gingipains RgpA, RgpB, and Kgp. Nakayama M, Inoue T, Naito M, Nakayama K, Ohara N. J Biol Chem. 2015 Feb 20;290(8):5190-202. doi: 10.1074/jbc.M114.591610. Epub 2015 Jan 6. PubMed |
| Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. Bieniasz M, Radhakrishnan P, Faham N, De La O JP, Welm AL. Clin Cancer Res. 2015 Dec 15;21(24):5588-600. doi: 10.1158/1078-0432.CCR-14-3283. Epub 2015 Aug 19. PubMed |
Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumor formation in mice via AKT2/mTORC1 cascade.
Wang C, Che L, Hu J, Zhang S, Jiang L, Latte G, Demartis MI, Tao J, Gui B, Pilo MG, Ribback S, Dombrowski F, Evert M, Calvisi DF, Chen X.
Liver Int. 2015 Dec 30. doi: 10.1111/liv.13055.
PubMed
Associated Plasmids |
| Class I PI-3-Kinase Signaling Is Critical for Bone Formation through Regulation of SMAD1 Activity in Osteoblasts. Gamez B, Rodriguez-Carballo E, Graupera M, Rosa JL, Ventura F. J Bone Miner Res. 2016 Feb 20. doi: 10.1002/jbmr.2819. PubMed |
| LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer. Henry WS, Hendrickson DG, Beca F, Glass B, Lindahl-Allen M, He L, Ji Z, Struhl K, Beck AH, Rinn JL, Toker A. Oncotarget. 2016 Dec 13;7(50):81981-81994. doi: 10.18632/oncotarget.11962. PubMed |
| Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. Nat Genet. 2017 Dec;49(12):1693-1704. doi: 10.1038/ng.3990. Epub 2017 Nov 6. PubMed |
| A Preexisting Rare PIK3CA(E545K) Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FCL, Li J, Teh JLF, Aplin AE, Chen M, Zhang J, Lazar AJ, Davies MA, Futreal PA, Amaria RN, Zhang DY, Wargo JA, Kwong LN. Cancer Discov. 2018 May;8(5):556-567. doi: 10.1158/2159-8290.CD-17-0745. Epub 2018 Mar 1. PubMed |
| The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. Lin R, Xia S, Shan C, Chen D, Liu Y, Gao X, Wang M, Kang HB, Pan Y, Liu S, Chung YR, Abdel-Wahab O, Merghoub T, Rossi M, Kudchadkar RR, Lawson DH, Khuri FR, Lonial S, Chen J. Mol Cell. 2018 Mar 15;69(6):923-937.e8. doi: 10.1016/j.molcel.2018.02.010. PubMed |
| PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition. McNeill RS, Stroobant EE, Smithberger E, Canoutas DA, Butler MK, Shelton AK, Patel SD, Limas JC, Skinner KR, Bash RE, Schmid RS, Miller CR. PLoS One. 2018 Jul 5;13(7):e0200014. doi: 10.1371/journal.pone.0200014. eCollection 2018. PubMed |
| The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J. Cancer Cell. 2018 Sep 10;34(3):427-438.e6. doi: 10.1016/j.ccell.2018.08.008. PubMed |
| Regulation of glioma cell invasion by 3q26 gene products PIK3CA, SOX2 and OPA1. Schaefer T, Ramadoss A, Leu S, Tintignac L, Tostado C, Bink A, Schurch C, Muller J, Scharer J, Moffa G, Demougin P, Moes S, Stippich C, Falbo S, Neddersen H, Bucher H, Frank S, Jeno P, Lengerke C, Ritz MF, Mariani L, Boulay JL. Brain Pathol. 2018 Nov 7. doi: 10.1111/bpa.12670. PubMed |
| A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells. Ghezzi C, Wong A, Chen BY, Ribalet B, Damoiseaux R, Clark PM. Nat Commun. 2019 Nov 29;10(1):5444. doi: 10.1038/s41467-019-13334-8. PubMed |
| Distinct epithelial-to-mesenchymal transitions induced by PIK3CA(H1047R) and PIK3CB. Gjelaj E, Hamel PA. J Cell Sci. 2021 Feb 17;134(4):jcs248294. doi: 10.1242/jcs.248294. PubMed |
| The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K-Akt Pathways. Candido S, Salemi R, Piccinin S, Falzone L, Libra M. Pharmaceutics. 2022 Mar 8;14(3). pii: pharmaceutics14030590. doi: 10.3390/pharmaceutics14030590. PubMed |
| USP28 enables oncogenic transformation of respiratory cells, and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K. Prieto-Garcia C, Hartmann O, Reissland M, Braun F, Bozkurt S, Pahor N, Fuss C, Schirbel A, Schulein-Volk C, Buchberger A, Calzado Canale MA, Rosenfeldt M, Dikic I, Munch C, Diefenbacher ME. Mol Oncol. 2022 Sep;16(17):3082-3106. doi: 10.1002/1878-0261.13217. Epub 2022 Apr 30. PubMed |
| Functional impact and molecular binding modes of drugs that target the PI3K isoform p110delta. Hassenruck F, Farina-Morillas M, Neumann L, Landini F, Blakemore SJ, Rabipour M, Alvarez-Idaboy JR, Pallasch CP, Hallek M, Rebollido-Rios R, Krause G. Commun Biol. 2023 Jun 5;6(1):603. doi: 10.1038/s42003-023-04921-z. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.